血栓通联合依达拉奉治疗急性脑梗死患者的临床疗效及安全性分析  

Clinical Efficacy and Safety of Xueshuantong Combined with Edaravone in the Treatment of Patients with Acute Cerebral Infarction

作　　者：赵娇 ZHAO Jiao(The Second People's Hospital of Liaoyang,Liaoyang 111000,China)

机构地区：[1]辽宁省辽阳市第二人民医院,辽宁辽阳111000

出　　处：《中国医药指南》2021年第30期114-115,共2页Guide of China Medicine

摘　　要：目的评价血栓通+依达拉奉对急性脑梗死患者进行治疗的临床效果和安全性。方法本文行分组对照试验,将2018年1月至2019年10月的76例急性脑梗死患者应用抽签法分为观察组和对照组,两组例数等量,均为38例。观察组行血栓通+依达拉奉法治疗研究,对照组行常规单一的依达拉奉治疗研究,分别计算两组相关数据统计结果,并做统计学比较。结果观察组联合治疗后的总有效率为89.47%(34/38),对照组单一治疗后的总有效率为65.79%(25/38),有明显差异,P<0.05;观察组联合用药的不良反应发生率为13.16%(5/38),对照组单一用药的不良反应发生率为10.53%(4/38),差异不显著,P>0.05;对两组患者护理以后的认知功能状况(MoCA量表和MMSE量表)进行比较,观察组明显比对照组表现更好,P<0.05,存在统计学差异性。结论临床对急性脑梗死患者应用血栓通+依达拉奉所取得的效果明显优于单纯的依达拉奉治疗,而且治疗过程中具有良好的安全性,可在一定程度上改善患者的认知功能障碍,值得推广。Objective To evaluate the clinical efficacy and safety of Xueshuantong and Edaravone in the treatment of patients with acute cerebral infarction.Methods A total of 76 patients with acute cerebral infarction from January 2018 to October 2019 were divided into observation group and control group.The number of cases was equal to 38 cases.The observation group underwent the treatment of Xueshuantong and Edaravone,and the control group underwent routine single edaravone treatment study.The statistical data of the two groups were calculated and compared statistically.Results The total effective rate of the observation group after treatment was 89.47%(34/38),and the total effective rate after single treatment in the control group was 65.79%(25/38),P<0.05.The adverse reactions occurred rate of the combination group in the observation group was 13.16%(5/38),and the incidence of adverse reactions in the control group was 10.53%(4/38),P>0.05.The cognitive function status(MoCA scale and MMSE amount table)after treatment in the two groups of patients)comparison,the observation group was significantly better than the control group,P<0.05,there was statistical difference.Conclusion The clinical application of Xueshuantong and Edaravone in patients with acute cerebral infarction is better than that of edaravone alone,and it has good safety during treatment,which can improve patient's cognition to some extent.Dysfunction is worth promoting.

关 键 词：急性脑梗死 血栓通 依达拉奉 

分 类 号：R743.33[医药卫生—神经病学与精神病学]